Background: Toxoplasmosis is an infectious disease caused by Toxoplasma gondii. The Toxoplasma gondii strain has an impact on the severity of toxoplasmosis. The severity of infection is mostly determined by the host's immune response, with infections in immunocompetent people typically asymptomatic. Infection can induce neurological, ocular, and systemic disorders in immunocompromised patients.
Nanomedicine developments appear promising, allowing toxoplasmosis to be treated with nanotechnology.
Aim
The aim of the present work was assessment the effect of ciprofloxacin and ciprofloxacin loaded on silver nanoparticles on murine acute toxoplasmosis.
Materials and methods
Mice were divided into 7 groups.
Group I:Non Infected non-treated mice (5mice),Group II: Infected with acute strain (RH) non-treated mice (10 mice),Group III: Infected mice treated with Spiramycin 100mg/kg 10 mice),Group IV: Infected mice treated with ciprofloxacin 100mg/kg.(10 mice),Group V: Infected mice treated with ciprofloxacin loaded silver nanoparticles 100mg/kg.(10 mice),Group VI: Infected mice treated with silver nanoparticles(10 mice).GroupVII:non infected treated with silver nanoparticles(5mice).
Effect of treatment was assessed by counting the number of tachyzoites in peritoneal fluid,survival rate and histopathological assessment of liver.
Results
Ciprofloxacin treated group showed significant reduction in tachyzoite count in peritoneal fluid, induced morphological alteration in shape of tachyzoites and improved histopathological picture in liver tissue but didn't significantly improve survival rate in infected mice.
The effect of Ciprofloxacin was augmented after loading it on silver nanoparticles.
Conclusion
Ciprofloxacin proved its effectiveness against experimental acute toxoplasmosis and its effect was augmented after loading it on silver nanoparticles.